Cost impact of different treatment regimens of brolucizumab in neovascular age-related macular degeneration: A budget impact analysis.

Siddiqui, Zasim Azhar; Dhumal, Trupti; Patel, Jay; LeMasters, Traci; Almony, Arghavan; Kamal, Khalid M

Siddiqui, Zasim Azhar; Dhumal, Trupti; Patel, Jay; LeMasters, Traci; Almony, Arghavan; Kamal, Khalid M.

Afiliação

Siddiqui ZA; School of Pharmacy, West Virginia University, Morgantown.
Dhumal T; School of Pharmacy, West Virginia University, Morgantown.
Patel J; College of Public Health, Temple University, Philadelphia, PA.
LeMasters T; School of Pharmacy, West Virginia University, Morgantown.
Almony A; Carolina Eye Associates, Southern Pines, NC, and School of Osteopathic Medicine, Campbell University, Lillington, NC.
Kamal KM; School of Pharmacy, West Virginia University, Morgantown.

J Manag Care Spec Pharm ; 28(12): 1350-1364, 2022 Dec.

Article em En | MEDLINE | ID: mdl-36427338

Assuntos

Anticorpos Monoclonais Humanizados; Degeneração Macular; Humanos; Anticorpos Monoclonais Humanizados/uso terapêutico; Orçamentos; Protocolos Clínicos; Degeneração Macular/tratamento farmacológico

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos Monoclonais Humanizados / Degeneração Macular Tipo de estudo: Guideline / Health_economic_evaluation / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: J Manag Care Spec Pharm Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google